Physician profile
Paul C Lee
NPI 1518919182
$12,251.24
in general payments reported to CMS, 2019-2025
34 companies · $2,397 in 2025
The $2,397 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,228 · 2020: $929 · 2021: $652 · 2022: $1,367 · 2023: $1,653 · 2024: $2,025 · 2025: $2,397.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,035 · Education: $40.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,034.77 |
| Education | $40.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $1,789.45 | 2021-2025 | |
| Abbott Laboratories | $1,515.20 | 2019-2025 | Aveir |
| Astrazeneca Pharmaceuticals LP | $1,417.74 | 2019-2025 | Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $923.52 | 2019-2025 | Jardiance |
| Amgen INC. | $916.13 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $691.50 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $577.19 | 2019-2025 | Eliquis, Camzyos |
| Merck Sharp & Dohme LLC | $550.66 | 2019-2025 | Verquvo |
| Pfizer INC. | $544.27 | 2019-2025 | |
| Abiomed | $516.25 | 2025 | |
| Amarin Pharma, INC. | $397.38 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $380.93 | 2020-2024 | |
| Glaxosmithkline, LLC. | $348.96 | 2019-2021 | |
| Boston Scientific Corporation | $309.01 | 2019-2025 | Watchman Flx |
| Lilly USA, LLC | $275.33 | 2019-2023 | Mounjaro |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $271.30 | 2019-2025 | Ozempic, Rybelsus |
| Esperion Therapeutics, INC. | $163.10 | 2021-2024 | Nexletol, Nexlizet |
| Intuitive Surgical, INC. | $123.45 | 2024 | |
| Axsome Therapeutics, INC. | $120.75 | 2023 | Auvelity |
| Endologix LLC | $74.23 | 2025 | Torus Stent Graft System, Endocross Device |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $51.71 | 2019 | |
| Alnylam Pharmaceuticals INC. | $48.08 | 2025 | Amvuttra |
| Biotronik INC. | $33.00 | 2024 | Amvia Edge |
| Medtronic, INC. | $31.02 | 2022 | |
| Janssen Pharmaceuticals, INC | $30.02 | 2019 | |
| Scpharmaceuticals INC. | $25.22 | 2025 | |
| Medtronic Vascular, INC. | $22.72 | 2019 | |
| Optinose US, INC. | $20.40 | 2019 | |
| Genentech USA, INC. | $19.83 | 2019 | |
| Sanofi Pasteur INC. | $14.52 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.48 | 2019 | |
| Allergan, INC. | $11.67 | 2019 | |
| Hikma Pharmaceuticals USA | $11.29 | 2019 | |
| Arbor Pharmaceuticals, INC. | $10.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.